Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Encorium releases second-quarter 2009 results

Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced its financial results for the second quarter ended June 30, 2009.

24 Aug 2009

Simcere to collaborate with Sun Yat-Sen University Cancer Center to research and develop anti-cancer drugs

Located in Guangzhou, Sun Yat-Sen University Cancer Center is one of China's renowned cancer research institutions, prominent in pre-clinical and clinical oncology research. The Sun Yat-Sen University Cancer Center was established to research anti-cancer treatments with a specific focus on developing major innovative drugs.

24 Aug 2009

Thomson Reuters to supply real-time clinical surveillance solution to Bryanlgh Health System

BryanLGH Health System has selected Clinical Xpert CareFocus from Thomson Reuters to play an integral role in its ongoing efforts to improve clinical quality and patient safety.

24 Aug 2009

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.

24 Aug 2009

New noninvasive technique to detect colorectal and gastric cancers found

A preliminary evaluation of methylation of two gene promoters in fecal DNA showed promise as a noninvasive method to detect colorectal and gastric cancers, according to a new study published online August 21 in the Journal of the National Cancer Institute.

24 Aug 2009

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the Western world. Fortunately physicians today have an abundance of drug therapies available to improve survival length for more advanced cancer patients. Now the discovery of genetic biomarkers relevant to CRC means that targeted personalised medication is increasingly common.

24 Aug 2009

FDA issues complete response letter regarding the NDA for carisbamate

The U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for carisbamate, an anti-epileptic drug in development, announced Ortho-McNeil-Janssen Pharmaceuticals, Inc.

23 Aug 2009

Ron Demuth of ChemDiv announces extension of collaboration with Lilly

ChemDiv, Inc. announced the expansion of its drug discovery collaboration with Eli Lilly through 2010. Under the terms of the agreement, the partners will identify and develop leads for an additional therapeutic target using ChemDiv's small molecule resources (the industry's largest commercial collection) and Discovery outSource™ drug discovery and development platforms.

21 Aug 2009

CEL-SCI to raise $4.4 million by selling 9.7 million units to institutional investors

CEL-SCI Corporation. (NYSE Amex: CVM), a biotechnology company entering a late stage oncology trial and focused on infectious disease, today announced that it has entered into a definitive agreement with several institutional investors to sell 9.7 million units, with each unit consisting of one of the Company's common shares and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $4.4 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.

21 Aug 2009

Takeda Canada reacquires commercial rights for an oral type 2 diabetic treatment drug

Takeda Canada, Inc. announced that it has reacquired the Canadian commercial rights to ACTOS(R) (pioglitazone HCl), an oral treatment for type 2 diabetes, from Eli Lilly Canada Inc. Takeda, the discoverer of ACTOS, licensed the drug to Lilly as part of a worldwide agreement in 1999.

21 Aug 2009

Southern Research's Birmingham campus to have a Comprehensive Chemical Biology Center

Southern Research Institute today announced that it has been selected as one of 11 organizations to help establish the National Cancer Institute's (NCI) Chemical Biology Consortium (CBC)--a program meant to coordinate and accelerate the discovery and development of new therapeutic agents to treat cancer patients. Southern Research will establish one of NCI's five Comprehensive Chemical Biology Centers at its Birmingham campus.

21 Aug 2009

Agreement provides International Oncology Network with preferential access to Altos Solutions’ OncoEMR system

International Oncology Network (ION), a business unit of AmerisourceBergen’s Specialty Group, has entered into an agreement with Altos Solutions that gives ION’s membership of community-based oncology practices preferred access to OncoEMR, Altos Solutions’ electronic medical records (EMR) system.

21 Aug 2009

Hospitals treating more black cancer patients experience worse survival rates

Hospitals that treat more black cancer patients have worse survival rates on average for patients with breast and colon cancer, regardless of race, according to a new study from the University of Michigan Comprehensive Cancer Center.

21 Aug 2009

Angiotech Pharmaceuticals plans US launch of Option Inferior Vena Cava Filter

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today announced the commercial launch of the Option(TM) Inferior Vena Cava (IVC) Filter in the United States, following FDA 510(k) clearance in June and a limited pre-launch in July. Angiotech holds exclusive worldwide rights to market and distribute the Option IVC Filter, which it obtained in a license agreement with privately held Rex Medical, LP (Rex Medical), as announced in March 2008.

20 Aug 2009

Poniard Pharmaceuticals may sell up to $60 million of its registered common stock to finance its picoplatin clinical development and commercialization programs

...

20 Aug 2009

Varian Medical Systems to equip a new proton therapy center in Sweden

Varian Medical Systems today announced it has been selected to equip a new proton therapy center in Sweden. In a ceremony conducted by Swedish authorities yesterday following a public tender, Varian was named to supply an estimated $60 million in products for Skandionkliniken, a new national proton therapy center owned by a consortium of seven of Sweden's counties.

20 Aug 2009

Managing Myeloma educational website launches forum to encourage oncology nurses to discuss myeloma challenges

Managing Myeloma (www.ManagingMyeloma.com), an accredited educational website for multidisciplinary professionals, has launched a forum designed specifically for oncology nurses. The goal of the nursing forum is to share insight about day-to-day practice challenges in caring for patients with multiple myeloma, provide updates on clinical advances, and connect with peers.

20 Aug 2009

Siemens' state-of-the-art high-definition PET/CT scanner installed at Long Beach PET Imaging Center

Long Beach PET Imaging Center, a leading diagnostic imaging center in the Long Beach, Calif.-area, announced today it has completed the installation of a new state-of-the-art HD (high-definition) PET/CT scanner, the first of its kind in the area.

20 Aug 2009

Vanderbilt enters Chemical Biology Consortium as a Chemical Diversity Center to develop cancer treatment drugs

Vanderbilt University has been selected as one of 10 centers in the nation to participate in the Chemical Biology Consortium (CBC), a major new initiative to facilitate the discovery and development of new agents to treat cancer.

20 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

Oncology News and Research

Further Reading

Encorium releases second-quarter 2009 results

Simcere to collaborate with Sun Yat-Sen University Cancer Center to research and develop anti-cancer drugs

Thomson Reuters to supply real-time clinical surveillance solution to Bryanlgh Health System

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

New noninvasive technique to detect colorectal and gastric cancers found

Discovery of genetic biomarkers enable targeted personalised medication for Colorectal cancer

FDA issues complete response letter regarding the NDA for carisbamate

Ron Demuth of ChemDiv announces extension of collaboration with Lilly

CEL-SCI to raise $4.4 million by selling 9.7 million units to institutional investors

Takeda Canada reacquires commercial rights for an oral type 2 diabetic treatment drug

Southern Research's Birmingham campus to have a Comprehensive Chemical Biology Center

Agreement provides International Oncology Network with preferential access to Altos Solutions’ OncoEMR system

Hospitals treating more black cancer patients experience worse survival rates

Angiotech Pharmaceuticals plans US launch of Option Inferior Vena Cava Filter

Poniard Pharmaceuticals may sell up to $60 million of its registered common stock to finance its picoplatin clinical development and commercialization programs

Varian Medical Systems to equip a new proton therapy center in Sweden

Managing Myeloma educational website launches forum to encourage oncology nurses to discuss myeloma challenges

Siemens' state-of-the-art high-definition PET/CT scanner installed at Long Beach PET Imaging Center

Vanderbilt enters Chemical Biology Consortium as a Chemical Diversity Center to develop cancer treatment drugs

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Cancer Research eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News